How This $4.3B Pharma Company Is Helping Underserved Patients in NeuroBy Press Room7 August 2024 For over 30 years, Richard Pops has been the CEO of Alkermes (NASDAQ: ALKS), a company steadfastly focused on neuroscience—a…